Two years ago, biotech company Medtronic launched an updated version of Reveal linq for its Reveal heart detector. The company has an ambitious expectation that the annual sales of the product will peak as much as $1-20 billion. Now, the company has recently released a year-long post-marketing follow-up survey data showing that the device has significant advantages in monitoring atrial fibrillation. This device is only one-third the size of an AAA battery, only one-tenth the size of its predecessor Reveal. Clinically, after the doctor implants the device into the upper left side of the chest, the monitor can wirelessly transmit heart rate information. At the same time, the battery of this device can support the device to run in the patient for up to three years. This time, the researchers followed a total of 1,247 patients with cryptogenic stroke in the United States to examine the number and duration of atrial fibrillation in these patients over a period of one year. The results showed that 192 patients had 1737 atrial fibrillation, and the rate of Reveal linq was 16.3%, which was 32% higher than that of the control group using the traditional test method. According to existing research, the probability of a second stroke episode is higher than that of the first time. According to the National Stroke Association of the United States, the number of strokes per year in the United States is as high as 800,000, of which the number of secondary episodes accounts for one quarter. There are many. The current treatment guidelines stipulate that a cardiac monitoring test with a total length of more than 30 days is required within six months of the patient's cryptogenic stroke. However, according to company surveys, if only 30-day heart rate levels are monitored, 72% of patients cannot be diagnosed. This also means that for these patients, real-time monitoring of cardiac function is very important. In May of last year, Medtronic conducted a study on Reveal linq to help clinicians determine when to take measures to avoid secondary stroke in stroke patients. Lose Weight Mints,Lose Breath Mints,Best Lose Weight Mints,Lose Weight Dental Probiotic Soar Biotech Co.,Ltd , https://www.xylitgum.com